The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. A
The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject.
대표청구항▼
It is claimed: 1. A powder composition comprising an active agent and a dipeptide or tripeptide comprised of at least two leucines, wherein about a 0.2% aqueous solution of the di-or tri-peptide is capable of reducing a surface tension of said solution to about 60 mN/m or less, as measured after ab
It is claimed: 1. A powder composition comprising an active agent and a dipeptide or tripeptide comprised of at least two leucines, wherein about a 0.2% aqueous solution of the di-or tri-peptide is capable of reducing a surface tension of said solution to about 60 mN/m or less, as measured after about 49 seconds, wherein the composition comprises particles having an MMD of less than about 10 microns, and wherein the active agent is not follicle stimulating hormone. 2. The composition of claim 1, in aerosolized form. 3. The composition of claim 1, further comprising a propellant. 4. The composition of claim 3, wherein the propellant is selected from the group consisting of a chlorofluorocarbon, a fluorocarbon, and combinations thereof. 5. The composition of claim 4, wherein the propellant comprises a chlorofluorocarbon or fluorocarbon. 6. The composition of claim 1, wherein the composition is suitable for delivery to the lung or deep lung by inhalation. 7. The composition of claim 1, wherein the di-or tripeptide is present in the composition from about 1% by weight to about 99% by weight. 8. The composition of claim 7, wherein the di-or tripeptide is present in the composition from about 2% by weight to about 75% by weight. 9. The composition of claim 8, wherein the di-or tripeptide is present in the composition from about 5% by weight to about 50% by weight. 10. The composition of claim 1, further comprising a pharmaceutically acceptable excipient or carrier. 11. The composition of claim 10, wherein the excipient is selected from the group consisting of carbohydrates, amino acids, peptides, proteins, organic acid salts, and polymers. 12. The composition of claim 1, comprising a dipeptide. 13. The composition of claim 1, comprising a tripepticie. 14. The composition of claim 13, wherein the tripeptide is selected from the group consisting of leu-leu-gly, leu-leu-ala, leu-leu-val, leu-leu-leu, leu-leu-ile, leu-leu-met, leu-leu-pro, leu-leu-phe, leu-leu-trp, leu-leu-ser, leu-leu-thr, leu-leu-cys, leu-leu-tyr, leu-leu-asp, leu-leu-glu, leu-leu-lys, leu-leu-arg, leu-leu-his, leu-leu-nor, leu-gly-leu, leu-ala-leu, leu-val-leu, leu-ile-leu, leu-met-leu, leu-pro-leu, leu-phe-leu, leu-trp-leu, leu-ser-leu, leu-thr-leu, leu-cys-leu, leu-tyr-leu, leu-asp-leu, leu-glu-leu, leu-lys-leu, leu-arg-leu, leu-nor-leu, and combinations thereof. 15. The composition of claim 14, wherein the tripeptide is trileucine. 16. The composition of claim 1, wherein said active agent is selected from the group consisting of amikacin, tobramycin, gentamicin, vancomycin, ciprofloxacin, levofloxacin, polymixin, Dnase, insulin, cyclosporin, parathyroid hormone, VLA-4 inhibitors, interleukin-4R, thrombopoletin, c-peptide, amylin, pro-insulin, interleukin-1, interleukin-2, alpha-1-antitrypsin, budesonide, human growth hormone, growth hormone releasing hormone, interferon alpha, interferon beta, growth colony stimulating factor, keratinocyte growth factor, glial growth factor, tumor necrosis factor, leutinizing hormone releasing hormone, calcitonin, low molecular weight heparin, somatostatin, respiratory syncytial virus antibody, erythropoietin, Factor VIII, Factor IX, ceredase, cerezyme and analogues, agonists and antagonists thereof. 17. The composition of claim 1, wherein the dry powder is a spray-dried powder. 18. The composition of claim 15, wherein said active agent comprises a biologically active fragment or analog of parathymid hormone. 19. The composition of claim 16, wherein said active agent comprises a biologically active fragment or analog of parathyroid hormone.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (5)
Yamamoto Nakayuki (Shizuoka JPX) Sakakibara Hideo (Shizuoka JPX) Mizuno Kimio (Shizuoka JPX), Physiologically active peptide composition for nasal administration.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Dirix Cardina A. M. C. (Westervoort NLX) Kamp Hendrikus J. M. (Westervoort NLX) Sam Anthonius P. (Heesch NLX), Process for the preparation of biologically active material containing polymeric microcapsules.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.